The Rosen Law Firm is alerting shareholders of Vistagen Therapeutics, Inc. (VTGN) to a pending securities class action lawsuit with a critical March 16, 2026 deadline for lead plaintiff applications. The litigation targets investors who acquired company stock during the period from April 1, 2024 through December 16, 2025, a timeframe the complaint alleges coincided with material misrepresentations by the company.
According to the lawsuit, Vistagen made allegedly false and misleading statements regarding its investigational drug fasedienol and related clinical trial data from the PALISADE-3 study. The complaint contends that the company presented overly optimistic public statements while withholding material adverse information that subsequently became known to the market. Such allegations form the basis of typical securities fraud claims under federal law, which require plaintiffs to demonstrate that investors relied on misstatements when making investment decisions.
Investors seeking to participate in the litigation or serve as lead plaintiff must act before the March deadline. Legal counsel specializing in securities matters can advise shareholders on their potential claims and procedural requirements for class action participation. The case remains in early stages, and class certification has not yet been determined.